(Q46041319)

18 December 2017

title

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy (English)

1 reference

18 December 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

8

Eric J Small

1 reference

18 December 2017

author name string

Amy M Lin

1

1 reference

18 December 2017

Brian I Rini

2

1 reference

18 December 2017

Vivian Weinberg

3

1 reference

18 December 2017

Kristen Fong

4

1 reference

18 December 2017

Charles J Ryan

5

1 reference

18 December 2017

Jonathan E Rosenberg

6

1 reference

18 December 2017

Lawrence Fong

7

1 reference

18 December 2017

publication date

1 October 2006

1 reference

18 December 2017

published in

BJU International

1 reference

18 December 2017

volume

98

1 reference

18 December 2017

issue

4

1 reference

18 December 2017

page(s)

763-769

1 reference

18 December 2017

Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Prostate specific antigen only progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

PDGF receptors as cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06396.X

10.1111/J.1464-410X.2006.06396.X

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017